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Recent experimental evidence suggested that the synthetic peptide desmopressin (DDAVP) interferes tumor 
angiogenesis by inducing the formation of angiostatin. It is also known that DDAVP stimulates the endothelial release 
of von Willebrand factor, a key element in resistance to metastasis. Vasopressin V2 receptor agonists such as DDAVP 
seem to evoke dual angiostatic and antimetastatic effects, breaking cooperative interactions of tumor and endothelial 
cells during tumor progression. 
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Understanding cancer progression is only feasible in 
the context of detailed insights into the interactions of 
cancer cells with the tumor milieu. Such interactions are 
determined by structural and biochemical properties of 
the extracelullar matrix as well as by communication 
with non-neoplastic cells present in the tumor 
microenvironment such as cancer-associated fibroblasts, 
mesenchymal stem cells, lymphocytes, tumor-associated 
macrophages and endothelial cells
[1]
. During angiogene-
sis, endothelial cell proliferation and migration are 
induced which ultimately leads to formation of new 
blood vessels from the pre-existing vasculature 
[2]
. 
Physiologically, this process takes place during 
embryogenesis, the female reproductive cycle, and 
wound healing. 
In tumor angiogenesis, the ‘‘angiogenic switch’’ is 
turned on, causing the normally quiescent vasculature to 
constantly sprout new vessels, thus promoting tumor 
growth 
[3]
. A large number of endogenous molecules are 
involved in the regulation of the angiogenic process 
several of these have been studied for potential 
therapeutic applications 
[4]
. Therefore, the angiogenic 
switch can be represented as a balance, which tips toward 
neovascularization when angiogenesis-stimulating factors 
exceed angiogenesis-inhibiting factors. Angiogenesis 
stimulators include vascular endothelial growth factors 
(VEGF), epidermal growth factors, fibroblast growth 
factors, platelet-derived growth factors, and their 
associated tyrosine kinase receptors, and matrix 
metalloproteinases. Anti-angiogenic regulators include 
angiostatin, endostatin, tumstatin and thrombospondin-1. 
Angiostatin is an internal fragment of plasminogen 
containing at least three of its kringles and it is produced 
in the tumor stroma 
[5]
. Components of the plasminogen-
activator system, including the serine proteases urokinase 
-type (uPA) and tissue-type (tPA), are involved in the 
proteolytic conversion of plasminogen to angiostatin in 
vitro, although the in vivo processes are not fully 
understood 
[6,7]
. Complete inhibition of angiostatin 
formation by cell lines secreting uPA and/or tPA was 
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observed with specific serine protease inhibitors 
[6]
. 
Angiostatin inhibited endothelial cell migration and tube 
formation in vitro and was shown to be inversely 
correlated with VEGF 
[8]
. Using in vivo preclinical 
models of lung cancer it was also shown that exogenous 
administration of angiostatin potently blocked neovascu-
larization and growth of metastases 
[9]
. Despite showing 
clinical potential, one major disadvantage of angiostatin 




As previously mentioned, subtle changes in the 
relative balance of pro- and anti-angiogenic factors can 
activate the angiogenic switch. The switch begins with 
perivascular detachment and vessel dilation, followed by 
angiogenic sprouting, new vessel formation and matura-
tion, and the recruitment of perivascular cells. Angio-
genesis will continue as long as the tumor grows, and the 
blood vessels specifically feed hypoxic and necrotic areas 
of the tumor to provide it with essential nutrients and 
oxygen 
[12]
. Tumor vasculature is structurally and 
functionally abnormal characterized by increased vessel 
permeability, dilatation and tortuosity, reduced pericyte 
coverage, and abnormal basement membranes 
[13, 14]
.  
Leakiness of tumor blood vessels has been indicted as 
contributing directly to tumor growth and metastasis by 
increasing tumor interstitial pressure that facilitates efflux 
of cancer cells and by creating foci of hypoxia and 
acidosis 
[15,16]
. In addition, hypoxia upregulates the 
production of angiogenic factors by cancer and stromal 
cells, which further aggravate vessel disorganization and 
thereby fuel non-productive angiogenesis in an endless 
self-reinforcing loop. Abnormal tumor vessels can also 
impede the function of immune cells in tumors, as well as 
the transport and/or distribution of chemotherapeutics 
[17]
. 
The concept of reciprocal interactions between tumor 
and endothelial cells can be found in the earliest work on 
tumor-induced angiogenesis 
[18]
. It has been postulated 
that the complex interplay between tumors and their 
vasculature depends on more than perfusion alone and 
that tumor-endothelial cell crosstalk and paracrine modes 
of regulation must be considered 
[19]
. It seems that a 
deeper comprehension of these interactions will promote 
the design and development of novel mechanistically-
acting drugs. 
Recently, we reported for the first time that the 
synthetic peptide desmopressin (1-deamino-8-D-arginine 
vasopressin, DDAVP) is able to reduce tumor angiogene-
sis by inducing the formation of angiostatin. The 
compound stimulates the secretion of uPA by cancer 
cells, thus excising angiostatin from plasminogen by 
controlled proteolysis 
[20]
. DDAVP is an analog of the 
antidiuretic hormone vasopressin, firstly described in 
1967 
[21]
. In contrast to vasopressin, which binds to the 
different vasopressin receptors, DDAVP is a selective 
agonist for the V2 cell membrane receptor 
[22]
. This 
vasopressin receptor subtype is expressed in the kidney 
collecting duct, mediating the antidiuretic action, and is 
also present in endothelial cells, mediating most of the 
non-renal effects of DDAVP, including a potent 
hemostatic effect 
[23]
. The presence of vasopressin 
receptors was documented in various human cancer cell 
lines 
[24]
, including breast, colorectal and small cell lung 
cancer, among others. DDAVP exhibited modest 
cytostatic effects on receptor-expressing cancer cells 
[25]
. 
Such action was clearly mediated through agonist V2 
receptor signaling, and thus involved activation of 
adenylate cyclase followed by intracellular cAMP 
elevation and protein kinase A (PKA) activation. 
DDAVP has been used as a treatment of choice in von 
Willebrand disease, at least for minor bleedings and for 
surgical prophylaxis 
[26]
. The compound induces a rapid 
increase in circulating von Willebrand factor (VWF) by 
stimulating its release from Weibel-Palade bodies mainly 
from microvascular endothelial cells, through a specific 
agonistic action on V2 vasopressin receptors. 
Interestingly, recent studies have implicated VWF as a 
regulator of metastasis, playing a protective role against 
tumor cell dissemination in vivo 
[27]
. It appears that VWF 
can induce the death of metastatic cells early after their 
arrest in the microvasculature of the target organ. More 
recently, it was found that aggressive human breast and 
lung cancer cells with high levels of ADAM28 (a 
disintegrin and metalloproteinase 28) are able to avoid 
VWF-induced apoptosis at micrometastatic sites. 
ADAM28 binds and degrades VWF, thus favoring the 
survival of metastatic cells in the tissue microenviron-
ment 
[28]
. This novel experimental evidence accounts for 
the crucial role of VWF in resistance to metastasis. 
Previously, we reported that administration of DDAVP 
can inhibit the formation of blood-borne metastasis in an 
experimental animal model. At clinically relevant doses, 
DDAVP inhibited lymph node and lung metastasis from 
aggressive mammary tumors 
[29, 30]
. Considering the 
hemostatic and antimetastatic properties of DDAVP, we 
designed a pilot veterinary clinical trial in dogs with 
locally-advanced mammary cancer, administering the 
peptide at high doses by intravenous infusion, before and 
after excision of the primary tumor. Perioperative 
DDAVP was well tolerated using this short-term 
treatment approach, and significantly prolonged disease-
free and overall survival 
[31]
. An extended veterinary trial 
recently confirmed these observations, showing a reduced 
incidence of local relapses and lung metastasis in treated 
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animals having high-grade carcinoma 
[32]
. The perio-
perative period is therefore an attractive window of 
opportunity to modulate tumor-host interactions in order 
to reduce the risk of metastatic disease 
[33]
. 
The biological effects of perioperative administration 
of DDAVP on both endothelial and V2 receptor-
expressing cancer cells are complex, and required further 
investigations. Nonetheless, the peptide seems to induce a 
dual, reciprocal angiostatic and antimetastatic effect, 
breaking the cooperative function of cancer cells and 
endothelial cells during tumor progression. As schema-
tized in Figure 1, DDAVP induces a tumor-mediated 
production of angiostatin, a potent anti-angiogenic 
effector 
[20]
. At the same time, the compound also 
activates endothelial release of VWF 
[23]
, which in turn 
obstructs biological mechanisms of cancer spread and 
may cause apoptosis of micrometastatic cells arrested in 
the target organ 
[27]
. 
Peptides such as DDAVP have a great potential as 
therapeutic agents due to their ease of rational design and 
target specificity. We have developed a panel of novel 
vasopressin V2 receptor agonists, derivatized from 
DDAVP. The synthetic peptide 1-deamino-4-valine-5-
glutamine-8-D-arginine vasopressin (designnated [V4Q5] 
DDAVP) exhibited a significantly higher antitumor 
activity than the parental compound 
[34]
. Further studies 
with DDAVP and its analog are warranted to determine 
their potential in cancer therapy through modulation of 
tumor-endothelial cell interactions. 
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Figure 1. Hypothetical model for the effects of DDAVP on reciprocal interactions between tumor and endothelial 
cells. DDAVP triggers V2 receptor agonist signaling in both tumor and endothelial cells, causing adenylate cyclase 
activation followed by cAMP-dependent PKA activation. A) DDAVP stimulates tumor-mediated production of angiostatin, 
a strong angiogenesis inhibitor. The compound induces secretion of soluble uPA, favoring angiostatin generation by the 
proteolityc cleavage of plasminogen. B) Simultaneously, DDAVP activates endothelial release of VWF by exocytosis of 
Weibel-Palade bodies. VWF plays a protective role against tumor cell dissemination and may cause apoptosis of 
micrometastatic foci. 
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